Featured Publications
Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
Herrin J, Abraham NS, Yao X, Noseworthy PA, Inselman J, Shah ND, Ngufor C. Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment. JAMA Network Open 2021, 4: e2110703. PMID: 34019087, PMCID: PMC8140376, DOI: 10.1001/jamanetworkopen.2021.10703.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnticoagulantsAntifibrinolytic AgentsAtrial FibrillationClinical Decision-MakingCohort StudiesCross-Sectional StudiesFemaleFibrinolytic AgentsGastrointestinal HemorrhageHumansMachine LearningMaleMiddle AgedMyocardial IschemiaPredictive Value of TestsRetrospective StudiesRisk AssessmentThienopyridinesUnited StatesVenous ThromboembolismYoung AdultConceptsGastrointestinal bleedingIschemic heart diseaseCross-sectional studyThienopyridine antiplatelet agentAntithrombotic treatmentVenous thromboembolismAntiplatelet agentsRandom survival forestStudy cohortAtrial fibrillationValidation cohortHeart diseaseHAS-BLED risk scoreRetrospective cross-sectional studyCox proportional hazards regressionHAS-BLED scorePrior GI bleedPatients 18 yearsCohort of patientsEntire study cohortProportional hazards regressionOptumLabs Data WarehouseMedicare Advantage enrolleesPositive predictive valueRisk prediction model
2019
Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age
Abraham NS, Noseworthy PA, Inselman J, Herrin J, Yao X, Sangaralingham LR, Cornish G, Ngufor C, Shah ND. Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clinical Gastroenterology And Hepatology 2019, 18: 337-346.e19. PMID: 31108228, PMCID: PMC7386161, DOI: 10.1016/j.cgh.2019.05.017.Peer-Reviewed Original ResearchConceptsGastrointestinal bleedingAntiplatelet monotherapyGIB riskAntiplatelet agentsRisk of GIBCombination antithrombotic therapyDifferent antithrombotic regimensDifferent antithrombotic strategiesDrug exposure categoriesProportion of patientsNationwide claims dataMedicare Advantage enrolleesAntithrombotic regimensBleeding increasesAntithrombotic therapyAntithrombotic strategiesElderly patientsCombination regimensPatient ageCombination therapyPrimary diagnosisAntithrombotic drugsAntithrombotic agentsCardiovascular conditionsRetrospective analysis
2007
Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2007, 100: 1227-1232. PMID: 17920362, PMCID: PMC2715362, DOI: 10.1016/j.amjcard.2007.05.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArrhythmias, CardiacCaliforniaCohort StudiesEmergency Service, HospitalEmergency TreatmentFemaleFibrinolytic AgentsHospital MortalityHumansMaleMedical RecordsMyocardial InfarctionOutcome Assessment, Health CareRegistriesRetrospective StudiesThrombolytic TherapyTime and Motion StudiesTime FactorsConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNeedle timeFibrinolytic therapyMyocardial infarctionHospital mortalitySymptom onsetOdds ratioReperfusion strategyAdjunctive medicationsHospital arrivalShorter doorTimely administrationNational registryRepresentative cohortPatientsMortalityInfarctionTherapyIndependent effectsCohortMinutesSmaller centersOnsetImpact of delay
2006
Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI)
Bradley EH, Herrin J, Wang Y, McNamara RL, Radford MJ, Magid DJ, Canto JG, Blaney M, Krumholz HM. Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). American Heart Journal 2006, 151: 1281-1287. PMID: 16781237, DOI: 10.1016/j.ahj.2005.07.015.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPatients' clinical characteristicsBalloon timeClinical characteristicsDrug timeMyocardial infarctionProportion of patientsElevation myocardial infarctionHospital-level variationTreatment of patientsCross-sectional analysisHigh performing hospitalsReperfusion therapyNational registryHospitalPatientsRegression modelingECGDrugsInfarctionHierarchical regression modelingHospital performanceImportant quality indicatorMinutesGeometric mean